Do Most Pancreatic Cancers Have a KRAS Mutation?
Siddhartha Mukherjee says most pancreatic cancers have KRAS mutations. Peter Attia asked whether that was so, and whether the mutation makes an antigen a CAR T cell could attack.
Mukherjee says not really. KRAS produces an antigen in some patients, but most of KRAS is hidden inside, so most of KRAS is not a CAR T target. He says KRAS is a target for small molecules that shut off its function, a lock and a key, and that this is not immunotherapy. A second path he describes is a CAR T cell against a unique pancreatic antigen, even if that removed the pancreas. He says that antigen has not been found. He says people can live without an endocrine pancreas, as in type 1 diabetes, and that patients live after a Whipple removes enough of the organ.
From the transcript
We now know that ovarian cancer is not an ovarian cancer. It's really a fallopian tube cancer. Long story. We can talk about it later. But ovarian cancer cells have an antigen. It's very well known. Have more than one antigen. And there are multiple attempts at making CAR T cells against them. One of them is going to be successful. Good example.
What percentage of pancreatic cancers have KRAS mutations? Aren't most of them? Most of them have KRAS mutations. And does the KRAS mutation produce an antigen that we could target with a CAR T? Not really. It produces an antigen in some patients, but most of KRAS is hidden inside. Most of KRAS is not a CAR T target. Now, KRAS, I'm talking about KRAS.